Suchergebnisse - "Cook, Gordon"

PubPharm (21)

1

Impact of minimal residual disease (MRD) in salvage autologous stem cell transplantation for relapsed myeloma : results from the NCRI Myeloma X (intensive) trial

enthalten in: Bone marrow transplantation | 2024

von de Tute, R. | Cook, G. | Cairns, D. | +12

2

Redefining nonmeasurable multiple myeloma using mass spectrometry

enthalten in: Blood | 2022

von Giles, H. | Cook, M. | Drayson, M. | +12

3

Outcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trial

enthalten in: British journal of haematology | 2022

von Chan, W. | Counsell, N. | de Tute, R. | +24

4

COVID symptoms, testing, shielding impact on patient-reported outcomes and early vaccine responses in individuals with multiple myeloma

enthalten in: British journal of haematology | 2022

von Ramasamy, K. | Sadler, R. | Jeans, S. | +15

5

Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients

enthalten in: Haematologica | 2021

von Weinhold, N. | Salwender, H. | Cairns, D. | +15

6

Using depth of response to stratify patients to front line Autologous Stem Cell Transplant : results of the phase II PADIMAC Myeloma Trial

enthalten in: British journal of haematology | 2021

von Popat, R. | Counsell, N. | de Tute, R. | +18

7

Predicting ultrahigh risk multiple myeloma by molecular profiling : an analysis of newly diagnosed transplant eligible myeloma XI trial patients

enthalten in: Leukemia | 2020

von Shah, V. | Sherborne, A. | Johnson, D. | +41

8

Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with multiple myeloma receiving systemic anti-cancer therapy

enthalten in: British journal of haematology | 2020

von Cook, G. | John Ashcroft, A. | Pratt, G. | +14

9

Trial re-investment to build better research for better impact

enthalten in: Lancet (London, England) | 2019

von Fox, T. | Horne, G. | Craddock, C. | +6

10

Extended follow-up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat (MUK six open label, multi-centre phase I/II Clinical Trial)

enthalten in: British journal of haematology | 2019

von Popat, R. | Brown, S. | Flanagan, L. | +10